Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties

Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties

Antibody-based therapeutics represent an important class of biopharmaceuticals in cancer immunotherapy. CD3 bispecific T-cell engagers activate cytotoxic T-cells and have shown remarkable clinical outcomes against several hematological malignancies. The absence of a costimulatory signal through CD28...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdullah Elsayed, Christian Pellegrino, Louis Plüss, Frederik Peissert, Ramon Benz, Franziska Ulrich, Gudrun Thorhallsdottir, Sheila Dakhel Plaza, Alessandra Villa, Jacqueline Mock, Emanuele Puca, Roberto De Luca, Markus G. Manz, Cornelia Halin, Dario Neri
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
bispecific antibodies
cancer immunotherapy
CD28
CD3
monoclonal antibodies
phage display technology
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2220839
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items